You have 7 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

RAD51C mutation

Showing 1 - 25 of 3,061
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation Trial in Sacramento (Niraparib, Niraparib Tosylate Monohydrate,

Recruiting
  • ATM Gene Mutation
  • +16 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Oct 27, 2022

BARD1 Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation Trial in Houston, Seattle (Educational Intervention, Genetic

Recruiting
  • BARD1 Gene Mutation
  • +14 more
  • Educational Intervention
  • +3 more
  • Houston, Texas
  • +1 more
Jun 14, 2022

BRCA1 Gene Mutation, BRCA2 Gene Mutation, RAD51C Gene Mutation Trial in Netherlands (Risk-reducing salpingectomy with delayed

Recruiting
  • BRCA1 Gene Mutation
  • +5 more
  • Risk-reducing salpingectomy with delayed oophorectomy
  • Risk-reducing salpingo-oophorectomy
  • Tilburg, Brabant, Netherlands
  • +13 more
Nov 1, 2022

An Intervention to Increase Genetic Testing in Families Who May

Recruiting
  • BRCA1 Mutation
  • +21 more
  • Intervention Arm At-risk Relative/ARR Contacts
  • +5 more
  • Basking Ridge, New Jersey
  • +7 more
Nov 22, 2022

Deleterious BARD1 Gene Mutation, Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation Trial in United States

Active, not recruiting
  • Deleterious BARD1 Gene Mutation
  • +13 more
  • Laboratory Biomarker Analysis
  • +4 more
  • Chicago, Illinois
  • +8 more
Feb 25, 2022

Cascade Testing in Families With Newly Diagnosed Hereditary

Recruiting
  • BRCA-Mutated Ovarian Carcinoma
  • +7 more
  • CASCADE genetic screening
  • New York, New York
    NYU Langone Health
Apr 30, 2021

HER2-negative Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer Trial in Spain (Olaparib)

Recruiting
  • HER2-negative Breast Cancer
  • +2 more
  • Barcelona, Spain
  • +4 more
Apr 14, 2022

ARID1A Gene Mutation, ATM Gene Mutation, ATR Gene Mutation Trial in United States (Olaparib)

Recruiting
  • ARID1A Gene Mutation
  • +15 more
  • Scottsdale, Arizona
  • +4 more
Dec 13, 2022

Metastatic Castrate Resistant Prostate Cancer, BRCA1, BRCA2, PALB2 Genetic Mutations Trial in United States (Carboplatin,

Recruiting
  • Metastatic Castrate Resistant Prostate Cancer
  • +2 more
  • West Los Angeles, California
  • +13 more
Nov 23, 2022

Advanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer Trial in Stanford (Talazoparib Tosylate)

Active, not recruiting
  • Advanced Breast Cancer
  • +2 more
  • Talazoparib Tosylate
  • Stanford, California
    Stanford University Hospitals and Clinics
Nov 16, 2022

Ovarian Tumor Epithelial, Homologous Recombination Deficiency, BRCA1 Mutation Trial in Groningen, Leiden, Rotterdam (Functional

Recruiting
  • Ovarian Neoplasm Epithelial
  • +3 more
  • Functional RAD51 assay
  • Olaparib Oral Product
  • Groningen, Netherlands
  • +2 more
Mar 30, 2021

Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Kidney Cancer Trial in Baltimore (Olaparib)

Recruiting
  • Renal Cell Carcinoma
  • +4 more
  • Baltimore, Maryland
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Mar 14, 2022

Her-2 Negative Breast Cancer, HRR Gene Mutation Trial in Guangzhou (Camrelizumab, Fluzoparib, Nab-paclitaxel)

Recruiting
  • Her-2 Negative Breast Cancer
  • HRR Gene Mutation
  • Guangzhou, Guangdong, China
    First Affiliated Hospital, Sun Yat-Sen University
Mar 7, 2023

Advanced Malignant Solid Tumor, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma Trial in

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +44 more
  • Biopsy
  • +23 more
  • Birmingham, Alabama
  • +166 more
Feb 2, 2023

Ovarian Cancer, Fallopian Tube Cancer Trial in Houston (RIsk-Reducing Salpingectomy (RRS), Risk-Reducing Oophorectomy-RRO,

Recruiting
  • Ovarian Cancer
  • Fallopian Tube Cancer
  • RIsk-Reducing Salpingectomy (RRS)
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Frequency of Occult Breast Cancer After Prophylactic Mastectomy

Recruiting
  • Genetic Predisposition
  • +3 more
  • Histopathological confirmation
  • Karachi, Sindh, Pakistan
    Aga Khan University Hospital
Mar 15, 2023

Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem

Recruiting
  • Acute Myeloid Leukemia (AML)
  • Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)
  • Cincinnati, Ohio
  • +18 more
Jan 20, 2023

Ovarian Cancer Trial in Worldwide (Alpelisib, Olaparib, Paclitaxel)

Recruiting
  • Ovarian Cancer
  • Phoenix, Arizona
  • +116 more
Nov 25, 2022

Metastatic Pancreatic Cancer Trial in Lyon (Niraparib)

Not yet recruiting
  • Metastatic Pancreatic Cancer
  • Lyon, France
    Centre Léon Bérard
Jul 4, 2022

Prostate Trial in United States (Olaparib)

Recruiting
  • Prostate
  • Baltimore, Maryland
  • +3 more
Feb 14, 2022

Advanced Cancers Trial in Boston (LY2606368)

Active, not recruiting
Has Results
  • Advanced Cancers
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jan 18, 2022

Gastric Cancer, GastroEsophageal Cancer Trial in Aurora, Colorado Springs, Highlands Ranch (Pembrolizumab, Olaparib,

Recruiting
  • Gastric Cancer
  • GastroEsophageal Cancer
  • Aurora, Colorado
  • +2 more
Jan 4, 2023

Sarcoma, Sarcoma,Soft Tissue, Sarcoma of Bone Trial in Shanghai (Camrelizumab and fluzoparib with concurrent stereotactic body

Recruiting
  • Sarcoma
  • +2 more
  • Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT)
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University, School of Medici
Oct 3, 2023

Germline Mutations Associated With Hereditary Pancreatic Cancer

Recruiting
  • Pancreatic Cancer
  • Pancreatic Adenocarcinoma
  • Invitae Multi-Cancer Panel ®
  • Mexico City, Mexico
    Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubi
Mar 22, 2022

Metastatic Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7 Trial in New York, Nashville (Laboratory Biomarker Analysis,

Active, not recruiting
  • Metastatic Uveal Melanoma
  • Stage IV Uveal Melanoma AJCC v7
  • New York, New York
  • +2 more
Jun 29, 2022